FindTrial
Sign In

unfractionated heparin (UFH)

DRUG6 trials

Sponsors

GlaxoSmithKline, Stealth BioTherapeutics Inc., Pfizer, Bristol-Myers Squibb, Aplagon Oy

Conditions

AntithromboticChronic Limb-Threatening IschemiaDeep Vein ThrombosisEmbolism, PulmonaryHealthy VolunteersPeripheral Arterial Occlusive DiseasePulmonary EmbolismThrombosis, Venous

Phase 1

Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia
CompletedNCT01513200
Stealth BioTherapeutics Inc.Healthy Volunteers
Start: 2012-01-31End: 2012-02-29Updated: 2012-04-19
A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis
CompletedNCT03000673
Bristol-Myers SquibbAntithrombotic
Start: 2017-05-23End: 2017-10-23Updated: 2020-12-29

Phase 2

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
RecruitingNCT07352800
Aplagon OyChronic Limb-Threatening Ischemia, Peripheral Arterial Occlusive Disease
Start: 2026-01-29End: 2027-06-30Target: 42Updated: 2026-02-03

Phase 3

The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
CompletedNCT00911157
GlaxoSmithKlineThrombosis, Venous
Start: 2008-06-30End: 2009-11-30Updated: 2016-11-23
The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
CompletedNCT00981409
GlaxoSmithKlineEmbolism, Pulmonary
Start: 2007-07-31End: 2008-12-31Updated: 2016-12-16
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
CompletedNCT01780987
PfizerDeep Vein Thrombosis, Pulmonary Embolism
Start: 2013-01-31End: 2014-09-30Updated: 2016-06-23